Linezolid and Vancomycin, Alone and in Combination with Rifampin, Compared with Moxifloxacin against a Multidrug-Resistant and a Vancomycin-Tolerant Streptococcus pneumoniae Strain in an In Vitro Pharmacodynamic Model-Reference-Cited by-同舟云学术

Linezolid and Vancomycin, Alone and in Combination with Rifampin, Compared with Moxifloxacin against a Multidrug-Resistant and a Vancomycin-Tolerant Streptococcus pneumoniae Strain in an In Vitro Pharmacodynamic Model

Published:2003-06 Issue:6 Volume:47 Page:1984-1987
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Cha Raymond¹,Rybak Michael J.¹²

Affiliation:

1. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences

2. School of Medicine, Wayne State University, Detroit Receiving Hospital, Detroit, Michigan

Abstract

ABSTRACT Potential alternatives, including linezolid, adjunctive rifampin, and moxifloxacin, were evaluated against vancomycin-tolerant (P9802-020) and vancomycin-susceptible clinical isolates of Streptococcus pneumoniae in an in vitro pharmacodynamic model. Vancomycin exhibited maximal killing of 2-log 10 CFU/ml against P9802-020. Linezolid, moxifloxacin, and linezolid plus rifampin exhibited 99.9% killing against both isolates. These alternatives should be considered for further evaluation against vancomycin-tolerant S. pneumoniae .

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.47.6.1984-1987.2003

Reference20 articles.

1. In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model

2. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother.15(Suppl. A):125-130.

3. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model

4. Centers for Disease Control and Prevention. 1999. Defining the public health impact of drug-resistant Streptococcus pneumoniae : report of a working group. Morb. Mortal. Wkly. Rep. 45: RR-1.

5. Centers for Disease Control and Prevention. 1999. Geographic variation in penicillin resistance in Streptococcus pneumoniae—selected sites, United States, 1997. Morb. Mortal. Wkly. Rep.48:656-661.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of an HPLC-UV Method for Quantitation of Linezolid: Application to Resistance Study Using in vitro PK/PD Model;Infection and Drug Resistance;2021-12

2. Combined Retrospective Analysis of Seven Phase II and III Trials of the Efficacy of Linezolid in the Treatment of Pneumonia Caused by Multidrug-Resistant Streptococcus pneumoniae;CLIN THER;2010

3. Combined retrospective analysis of seven phase II and III trials of the efficacy of linezolid in the treatment of pneumonia caused by multidrug-resistant Streptococcus pneumoniae;Clinical Therapeutics;2010-12

4. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB;Future Medicinal Chemistry;2010-08

5. Pharmacological Issues of Linezolid;Clinical Pharmacokinetics;2010-07